Compare Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) vs Sibanye Stillwater Ltd (SBSW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Maravai LifeSciences Holdings Inc. Class A Common Stock vs Sibanye Stillwater Ltd — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $977.37M), while Sibanye Stillwater Ltd trades at $9.7 (market cap $6.73B). The key difference: Sibanye Stillwater Ltd is far larger — about 6.9× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Sibanye Stillwater Ltd pays a 8.59% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and Sibanye Stillwater Ltd for 51 Days on average.
| MRVI | SBSW | |
|---|---|---|
Market Cap | $977.37M | $6.73B |
Volume | 2,742,564 | 4,495,821 |
Sector | Health | Basic Materials |
52-Week High | $9.00 | $21.12 |
52-Week Low | $2.83 | $8.00 |
Typical Hold Time | 0 Days | 51 Days |
Enterprise Value | $1.08B | $7.64B |
Dividend Yield | — | 8.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Sibanye Stillwater (SBSW) trades at $9.91, up 0.2% on the day, with a bearish technical signal from moving averages and neutral oscillators. The company reported a net loss of $5.17 billion in 2025 despite revenue of $129.68 billion, though 2026 projections show a return to profitability. Recent news highlights strong first-half 2026 results, including 54% revenue growth and a 111% surge in EBITDA, signaling a potential turnaround.
The outlook is cautiously optimistic, with a consensus analyst price target of $14.25 offering significant upside. Key risks include volatile commodity prices and high debt levels, but improving cash flow and operational momentum support a recovery thesis. Investors should weigh the bullish analyst sentiment against ongoing profitability challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →About Sibanye Stillwater Ltd
Sibanye Stillwater Ltd is a South Africa-focused mining company. The Group currently owns and operates five underground and surface gold operations in South Africa: the Cooke, DRDGOLD, Driefontein, and Kloof operations in the West Witwatersrand region, and the Beatrix Operation in the southern Free State province. In addition to mining, the company owns and manages extraction and processing facilities at its operations, where gold-bearing ore is treated and beneficiated to produce gold dore. The gold dore is further refined at Rand Refinery into gold bars with a purity of at least 99.5% and is then sold on international markets. Sibanye holds a 44% interest in Rand Refinery, global refiners of gold, and the largest in Africa. Rand Refinery markets gold to customers around the world.
Read more on SBSW →
